This Week in Hematology — Jun 17, 2026

Welcome to This Week in Hematology. This week we're covering 8 notable papers spanning advances in diagnosing and treating lymphoma, new strategies in thrombosis and hemostasis, and innovations in cellular therapy and infectious disease management. Let's dive in.

We begin this week in malignant hematology, with new data on first-line therapy for mantle cell lymphoma, a powerful diagnostic tool for large B-cell lymphomas, and a better way to identify a dangerous complication of cancer. In the American Journal of Hematology, investigators report results from the CARiBOU trial, a phase 2 multicenter study testing a multi-targeted first-line regimen for mantle cell lymphoma [1]. The regimen employed alternating VR-CAP and R-cytarabine with continuous acalabrutinib for six cycles in an outpatient setting. Among 41 enrolled patients, the results were impressive: 90% achieved a complete metabolic response. Furthermore, among patients tested, 79% achieved undetectable measurable residual disease. At 18 months, the estimated progression-free survival was 79% and overall survival was 96%. Toxicities were primarily hematologic, with no treatment-related deaths. This study presents an efficient and highly effective outpatient regimen for newly diagnosed mantle cell lymphoma, which may allow for flexible, MRD-guided decisions on future consolidation and maintenance. Shifting from therapy to diagnostics, a study in Blood Advances explores the use of high-throughput chromosome conformation capture, or Hi-C sequencing, for diagnosing large B-cell lymphoma [2]. Using formalin-fixed paraffin-embedded tissues from 159 patients, this next-generation sequencing technique identified key gene rearrangements of MYC, BCL2, and BCL6, including 25 rearrangements that were completely missed by standard fluorescence in situ hybridization, or FISH. The authors note that these FISH-negative results were due to a variety of factors, including cryptic breakpoints or complex signals. Perhaps most strikingly, in nearly 13% of patients, Hi-C sequencing detected rearrangements characteristic of other lymphoma types, such as CCND1, which could lead to reclassification as mantle cell lymphoma. This study demonstrates that Hi-C sequencing is a highly sensitive and unbiased tool that can improve diagnostic precision and help guide treatment in large B-cell lymphoma. Rounding out our malignant hematology section, a report in the American Journal of Hematology offers new tools for diagnosing malignancy-associated hemophagocytic lymphohistiocytosis, or M-HLHa [3]. Investigators analyzed cytokine profiles from 112 adult patients and developed a cytokine-based Risk Score. Four variables were retained in the final model: age over 48 years, TNF-alpha below 43 picograms per milliliter, IL-18 above 574, and an IL-10 to IL-6 ratio of 1.5 or greater. A risk score of 20 or higher was associated with a 17-fold increased odds of having M-HLHa. The IL-10 to IL-6 ratio by itself also showed good performance. These findings suggest that this risk score and the IL-10/IL-6 ratio are useful tools to help clinicians more accurately identify adults with this dangerous syndrome.

Next, we turn to thrombosis and hemostasis, with a look at predicting cancer-associated thrombosis and long-term real-world data on emicizumab. Predicting venous thromboembolism in cancer patients remains a challenge, with existing models like the Khorana score showing limited accuracy. A study in Science Translational Medicine used high-throughput proteomics to tackle this problem [4]. Analyzing over 1100 plasma proteins from patients with newly diagnosed lung or gastric cancer, researchers developed a predictive model incorporating 11 protein biomarkers and five clinical parameters. This new model substantially outperformed the standard Khorana score. The analysis also provided mechanistic insights, highlighting the role of an immune checkpoint receptor, CD200R1, and suggesting that an IL-17-driven inflammatory state contributes to thrombosis. While not yet a clinical tool, this work represents a major step toward more accurate VTE prediction and identifies potential new therapeutic targets in thrombo-inflammatory disease. From thrombosis to bleeding, a study in the British Journal of Haematology provides long-term, real-world data on emicizumab prophylaxis for hemophilia A [5]. This multicenter retrospective study included 132 patients in China who received emicizumab for at least one year, with a median follow-up of 26 months. The therapy provided sustained bleeding control, with a model-based annualized bleeding rate of just 0.81. Critically for long-term outcomes, 96% of baseline target joints resolved, and no new target joints developed during the follow-up period. The safety profile was favorable, with no thromboembolic or fatal events observed. This large cohort study provides strong real-world evidence confirming the long-term efficacy and safety of emicizumab for providing sustained bleeding control and joint protection.

Finally, we'll cover a few papers with broad implications, from a key infectious disease question and cellular therapy for transplantation to a fascinating look at cellular aging. A paper in The New England Journal of Medicine addresses a common clinical dilemma: the choice of antibiotic for methicillin-susceptible Staphylococcus aureus bacteremia [6]. In an international Bayesian adaptive platform trial involving over 1200 adults, cefazolin was compared with an antistaphylococcal penicillin like flucloxacillin or cloxacillin. The primary outcome, 90-day mortality, was similar between the groups, at 15.0% in the cefazolin group and 17.0% in the penicillin group, meeting the criterion for noninferiority. However, cefazolin was associated with a significantly lower incidence of acute kidney injury—13.9% compared to 19.6%. This trial provides strong evidence that in patients with MSSA bacteremia, cefazolin is not only noninferior for mortality but is also safer for the kidneys, supporting its use as a preferred agent. Also pushing boundaries, a phase 1/2a trial in Science Translational Medicine tested a novel approach to induce tolerance in kidney transplantation [7]. Six patients undergoing living-donor kidney transplantation received a combination of donor bone marrow cells and recipient regulatory T cells immediately after their transplant. This cell therapy successfully induced total leukocyte donor chimerism in all six patients, an outcome not seen in any of the controls. Importantly, this was achieved without the need for toxic recipient irradiation. This chimerism was associated with decreased antidonor T cell reactivity, and three of the patients were able to have their immunosuppression minimized to belatacept monotherapy. This trial serves as a powerful proof of concept for a combination cell therapy that can induce chimerism-based immunomodulation without the need for myeloablation. We end this week with a broad, forward-looking study from Nature Medicine on cellular aging [8]. Researchers analyzed over 7,000 plasma proteins from more than 60,000 individuals to develop machine learning models that estimate the biological age of over 40 different cell types. They found that about a quarter of individuals showed accelerated aging in a single cell type. These cellular aging signatures were highly predictive of future disease. For example, extreme astrocyte aging tripled the risk of incident Alzheimer's Disease in APOE4 carriers, while extremely aged skeletal myocytes were associated with a more than 12-fold higher risk of developing amyotrophic lateral sclerosis. This work establishes a new framework for quantifying human physiology at a cellular level, revealing how heterogeneous aging across different tissues can influence disease susceptibility and resilience, with potential future applications in hematology for understanding conditions from clonal hematopoiesis to immune senescence.

If you only have time for one paper this week, make it the Hi-C sequencing study in Blood Advances [2]. It demonstrates how a single, next-generation sequencing assay can be more sensitive than FISH, uncover missed diagnoses, and reclassify lymphomas, highlighting a potential paradigm shift in routine pathology workflows.

Here are the key takeaways from this week in Hematology: First, in first-line mantle cell lymphoma, the outpatient CARiBOU regimen combining acalabrutinib with chemoimmunotherapy achieves very high rates of complete metabolic response and MRD negativity [1]. Second, for DLBCL diagnostics, Hi-C sequencing is a powerful tool that outperforms FISH, detecting more clinically relevant rearrangements and potentially altering diagnoses for over 10% of patients [2]. Third, when treating methicillin-susceptible staph aureus bacteremia, cefazolin is non-inferior to antistaphylococcal penicillins for mortality and causes less acute kidney injury, making it an excellent choice [6]. Finally, in hemophilia A, long-term real-world data from China confirms that emicizumab provides sustained, excellent bleeding control and joint protection with a favorable safety profile [5].

That's your roundup for This Week in Hematology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.